13FINSTITUTION · CIK 0001633313 · 2026-Q3 · Filed Nov 16, 2026
Avoro Capital Advisors
AVORO CAPITAL ADVISORS LLC
$9.7B
13F long value · 2026-Q3 Positions30
CategoryAsset manager
Quarters tracked10
●#472 of 556 by 13F long value
Size rank 2/10
5NEW2TRIM1EXIT
Snapshot
Avoro Capital Advisors's 13F portfolio at a glance: size, concentration and this quarter's activity.
13F long value
$9.7B
Positions
30 (1 unmapped)
Top 30 long weight
99.8%
Quarters tracked
10
Latest 13F filed
Nov 16, 2026
New positions
5
Exits / near-exits
1
13F long value by quarter
Reported long equity value each quarter: fund flows plus market moves. Option notional is not included.
Top holdings · 2026-Q3
The fund's largest reported positions. The long positions shown cover 99.8% of the long value.
| Ticker | Issuer | Weight | Value | Shares | Since 2026-Q3 |
|---|---|---|---|---|---|
| UTHR UNITED THERAPEUTICS Corp | UNITED THERAPEUTICS Corp | 15.4% | $1.5B | 2.8M | +8.5% |
| ASND Ascendis Pharma A/S | Ascendis Pharma A/S | 11.9% | $1.2B | 5.0M | +19.3% |
| KRYS Krystal Biotech, Inc. | Krystal Biotech, Inc. | 9.9% | $960.7M | 2.9M | -10.4% |
| ARGX ARGENX SE | ARGENX SE | 9.9% | $958.9M | 1.0M | -0.8% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | MADRIGAL PHARMACEUTICALS, INC. | 9.5% | $923.9M | 1.8M | -15.9% |
| KYMR Kymera Therapeutics, Inc. | Kymera Therapeutics, Inc. | 8.6% | $835.6M | 7.5M | +12.6% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | ARROWHEAD PHARMACEUTICALS, INC. | 7.4% | $720.0M | 11.0M | -32.5% |
| RVMD Revolution Medicines, Inc. | Revolution Medicines, Inc. | 4.5% | $440.3M | 2.1M | -18.7% |
| CYTK CYTOKINETICS INC | CYTOKINETICS INC | 3.3% | $323.0M | 4.9M | -19.3% |
| DFTX Definium Therapeutics, Inc. | Definium Therapeutics, Inc. | 2.8% | $268.3M | 7.0M | -20.8% |
| GPCR Structure Therapeutics Inc. | Structure Therapeutics Inc. | 2.1% | $205.0M | 6.6M | -40.6% |
| XENE Xenon Pharmaceuticals Inc. | Xenon Pharmaceuticals Inc. | 2.1% | $204.5M | 5.5M | +5.6% |
| VERA Vera Therapeutics, Inc. | Vera Therapeutics, Inc. | 1.9% | $182.0M | 5.6M | -16.5% |
| QURE uniQure N.V. | uniQure N.V. | 1.7% | $162.5M | 6.7M | -9.4% |
| CELC Celcuity Inc. | Celcuity Inc. | 1.2% | $119.3M | 1.5M | -23.8% |
Quarterly changes · 2026-Q3
What Avoro Capital Advisors opened, added, trimmed and exited this quarter, largest dollar moves first.
| Action | Ticker | Issuer | Prev shares | Curr shares | Change | Value Δ |
|---|---|---|---|---|---|---|
| TRIM | CELC TRIM Celcuity Inc. | Celcuity Inc. | 3.4M | 1.5M | -55.9% | -$236.4M |
| EXIT | No ticker EXIT DAMORA THERAPEUTICS INC | DAMORA THERAPEUTICS INC | 3.8M | 0 | -100.0% | -$98.4M |
| NEW | DMRA NEW Damora Therapeutics, Inc. | Damora Therapeutics, Inc. | 0 | 3.8M | New | +$80.5M |
| NEW | ABVX NEW Abivax S.A. | Abivax S.A. | 0 | 488.0K | New | +$48.3M |
| NEW | SCTX NEW Scribe Therapeutics, Inc. | Scribe Therapeutics, Inc. | 0 | 2.6M | New | +$47.8M |
| NEW | No ticker NEW BIOHAVEN LTD | BIOHAVEN LTD | 0 | 2.8M | New | +$36.7M |
| NEW | BRVE NEW Braveheart Bio, Inc. | Braveheart Bio, Inc. | 0 | 1.3M | New | +$25.4M |
| TRIM | LXEO TRIM Lexeo Therapeutics, Inc. | Lexeo Therapeutics, Inc. | 1.5M | 525.0K | -64.7% | -$5.2M |
Conviction over time
Portfolio weight of the current top long holdings, quarter by quarter; rising weight = growing conviction.